Posts with or without credits tagged 'reimaginemedicine'
- 26 posts
- 535 likes
- 117 shares
- 90 comments
11
1
48
11
1
48
Partnership and shared expertise can be the key to progress. Every day, we value the opportunity to #Reimaginemedicine together with the goal of reaching more cancer patients in need of additional treatment options like #Radioligandtherapy. #ASCO24
8
1
4
8
1
4
What motivates our experts in #Radioligandtherapy (RLT)? Every day, our team works to #Reimaginemedicine and leverage our expertise in RLT for patients around the world living with advanced cancers. #ASCO24
7
1
5
7
1
5
As pioneers in #RadioligandTherapy (RLT), we have bolstered our manufacturing capacity to meet present and future demand. It’s part of our aim to #ReimagineMedicine for people living with advanced cancers.
#ASCO24 t.co/Zvk05LLe9b
9
2
9
2
At our #RadioligandTherapy (RLT) manufacturing facilities, highly specialized associates race against the clock every day as they seek to advance our mission to #ReimagineMedicine for the patients who need it. t.co/l50h1wrCPD
8
1
8
1
As we continue to #ReimagineMedicine, we are pioneering technology to ensure a consistent and reliable experience for patients and their health care teams. t.co/SE67omL3Iy
11
3
2
11
3
2
We are investing in every aspect of #RadioligandTherapy (RLT) to deliver to patients. With a global footprint, industry-leading supply chain and clear vision for this treatment paradigm, we are committed to the present—and future—of RLTs.
#ReimagineMedicine
15
3
11
15
3
11
Every step of our #RadioligandTherapy (RLT) manufacturing process reflects our deep commitment to deliver these treatments to patients at the speed they need them. t.co/7cwTiFhMrv
#ReimagineMedicine
10
1
5
10
1
5
At #EAN2019 we are highlighting cognition data in SPMS. We are committed to improving the lives of people living with Secondary Progressive MS #ReimagineMedicine #NovartisNews
14
6
1
14
6
1
Today we are at #EAN2019 presenting results in #migraine reinforcing the long-term breadth of data for patients who failed prior #PreventiveTreatment. #NovartisNews #ReimagineMedicine
14
6
1
14
6
1
Breaking at #EHA24: Novartis presents new data on potential treatments for chronic myeloid leukemia (CML) #NovartisNews #reimaginemedicine
23
12
4
23
12
4
#NovartisNews 100+ abstracts for the most difficult-to-treat cancers and blood disorders at #ASCO19 and #EHA24 #ReimagineMedicine t.co/vo1JdeqDWz
21
5
21
5
#NovartisNews: For the first time, Novartis presents full data from head-to-head Phase III study in relapsing remitting #MS being presented at #AANAM2019 #reimaginemedicine t.co/qRQ4nVEbH4
23
6
23
6
#NovartisNews: New cognition data from Phase III Secondary Progressive #MS trial being presented at #AANAM2019 #reimaginemedicine
17
4
17
4
16
2
16
2
We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. #reimaginemedicine
36
12
1
36
12
1
We use innovative science and technology to address some of society’s most challenging healthcare issues. #reimaginemedicine
33
3
3
33
3
3
FY Results 2018: members of our Executive Team reflect on a remarkable year for the company and what to look forward to from Novartis in 2019. $NVS #NovartisNews #reimaginemedicine @VasNarasimhan @BBOD
42
5
2
42
5
2
The Digital Annual Review 2018 highlights our progress against the company’s five strategic priorities on an interactive page. #reimaginemedicine
26
3
26
3
24
3
1
24
3
1
Today at Basel HQ we announced our 2018 annual results. Get the highlights #NovartisNews #reimaginemedicine
31
5
31
5
16
2
1
16
2
1
29
9
1
29
9
1
With real-time and predictive analytics on the Nerve Live platform, we can understand the story our data is telling us. #gobigondata #reimaginemedicine
36
6
36
6
#BreakingNews: Data presented at the upcoming #ASH18 and #SABCS18 congresses will reinforce the strength of our pipeline and portfolio in hematology and oncology. #ReimagineMedicine #NovartisNews
34
10
34
10
SIGN UP FOR FREE TO KEEP EXPLORING! 🔐
To access more than the first page of results, sign in or sign up for an account!